(DH) Definitive Healthcare - Ratings and Ratios
Healthcare Intelligence, Analytics Platform, Provider Data, SaaS
DH EPS (Earnings per Share)
DH Revenue
Description: DH Definitive Healthcare October 25, 2025
Definitive Healthcare Corp. (NASDAQ:DH) operates a SaaS-based commercial intelligence platform that aggregates and curates data on U.S. and international healthcare providers. The platform is marketed to biopharma, medical-device, health-IT firms, and ancillary players such as staffing, real-estate, and financial services that serve the broader healthcare ecosystem.
Its product suite supports multiple functional workflows-including sales targeting, marketing analytics, clinical-research recruitment, product-development insight, strategic planning, talent acquisition, and physician-network management-enabling customers to move from concept to go-to-market execution with data-driven precision.
Founded in 2011 and headquartered in Framingham, Massachusetts, Definitive Healthcare sits in the Health Care Technology sub-industry (GICS) and has expanded its addressable market by leveraging the growing demand for granular provider-level data, a trend accelerated by the 2022-2023 surge in value-based care contracts and the FDA’s emphasis on real-world evidence.
Recent metrics (Q2 2024) show a 28% year-over-year increase in subscription ARR and a net-retention rate of 124%, reflecting strong customer stickiness and upsell potential. The company’s TAM is estimated at >$12 billion, driven by the projected 9% CAGR in health-tech spend and the expanding need for data to support AI-enabled drug discovery pipelines.
Analysts note that a key risk is the concentration of revenue among a handful of large biopharma clients; a 10% loss of a top-tier contract could materially depress earnings.
For a deeper dive into how Definitive Healthcare’s data assets compare to peers and to explore valuation angles, you might find ValueRay’s comparative analytics platform worth a look.
DH Stock Overview
| Market Cap in USD | 288m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2021-09-15 |
DH Stock Ratings
| Growth Rating | -75.2% |
| Fundamental | 50.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -42.3% |
| Analyst Rating | 3.29 of 5 |
DH Dividends
Currently no dividends paidDH Growth Ratios
| Growth Correlation 3m | -60.6% |
| Growth Correlation 12m | -41.6% |
| Growth Correlation 5y | -97.1% |
| CAGR 5y | -37.39% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.45 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.76 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | -60.27 |
| Beta | 1.649 |
| Volatility | 58.36% |
| Current Volume | 491.1k |
| Average Volume 20d | 238.8k |
| Stop Loss | 2.6 (-9.1%) |
| Signal | 0.70 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (-304.8m TTM) > 0 and > 6% of Revenue (6% = 14.7m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 3.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 39.99% (prev 83.12%; Δ -43.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 62.9m > Net Income -304.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (106.8m) change vs 12m ago -9.29% (target <= -2.0% for YES) |
| Gross Margin 76.35% (prev 69.26%; Δ 7.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.34% (prev 18.17%; Δ 4.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -35.82 (EBITDA TTM -399.9m / Interest Expense TTM 12.7m) >= 6 (WARN >= 3) |
Altman Z'' -1.96
| (A) 0.13 = (Total Current Assets 249.2m - Total Current Liabilities 151.3m) / Total Assets 770.1m |
| (B) -0.00 = Retained Earnings (Balance) -1.34m / Total Assets 770.1m |
| (C) -0.41 = EBIT TTM -454.3m / Avg Total Assets 1.10b |
| (D) -0.01 = Book Value of Equity -2.57m / Total Liabilities 358.9m |
| Total Rating: -1.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 50.47
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 45.36% = 5.0 |
| 3. FCF Margin 20.93% = 5.23 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 0.18 = 2.48 |
| 6. ROIC - WACC (= -92.18)% = -12.50 |
| 7. RoE -72.35% = -2.50 |
| 8. Rev. Trend 24.11% = 1.81 |
| 9. EPS Trend -40.86% = -2.04 |
What is the price of DH shares?
Over the past week, the price has changed by -3.70%, over one month by -16.37%, over three months by -25.52% and over the past year by -29.90%.
Is Definitive Healthcare a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DH is around 1.82 USD . This means that DH is currently overvalued and has a potential downside of -36.36%.
Is DH a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 9
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the DH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 58.7% |
| Analysts Target Price | 4.5 | 58.7% |
| ValueRay Target Price | 2.1 | -26.6% |
DH Fundamental Data Overview October 31, 2025
P/E Forward = 12.3305
P/S = 1.1772
P/B = 1.1416
Beta = 1.649
Revenue TTM = 244.9m USD
EBIT TTM = -454.3m USD
EBITDA TTM = -399.9m USD
Long Term Debt = 160.3m USD (from longTermDebt, last quarter)
Short Term Debt = 11.2m USD (from shortTermDebt, last quarter)
Debt = 8.92m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -72.1m USD (from netDebt column, last quarter)
Enterprise Value = 113.0m USD (288.3m + Debt 8.92m - CCE 184.2m)
Interest Coverage Ratio = -35.82 (Ebit TTM -454.3m / Interest Expense TTM 12.7m)
FCF Yield = 45.36% (FCF TTM 51.3m / Enterprise Value 113.0m)
FCF Margin = 20.93% (FCF TTM 51.3m / Revenue TTM 244.9m)
Net Margin = -124.4% (Net Income TTM -304.8m / Revenue TTM 244.9m)
Gross Margin = 76.35% ((Revenue TTM 244.9m - Cost of Revenue TTM 57.9m) / Revenue TTM)
Gross Margin QoQ = 76.73% (prev 73.93%)
Tobins Q-Ratio = 0.15 (Enterprise Value 113.0m / Total Assets 770.1m)
Interest Expense / Debt = 33.52% (Interest Expense 2.99m / Debt 8.92m)
Taxrate = -5.18% (negative due to tax credits) (456.0k / -8.81m)
NOPAT = -477.8m (EBIT -454.3m * (1 - -5.18%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.65 (Total Current Assets 249.2m / Total Current Liabilities 151.3m)
Debt / Equity = 0.02 (Debt 8.92m / totalStockholderEquity, last quarter 411.2m)
Debt / EBITDA = 0.18 (negative EBITDA) (Net Debt -72.1m / EBITDA -399.9m)
Debt / FCF = -1.41 (Net Debt -72.1m / FCF TTM 51.3m)
Total Stockholder Equity = 421.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.57% (Net Income -304.8m / Total Assets 770.1m)
RoE = -72.35% (Net Income TTM -304.8m / Total Stockholder Equity 421.2m)
RoCE = -78.12% (EBIT -454.3m / Capital Employed (Equity 421.2m + L.T.Debt 160.3m))
RoIC = -79.40% (negative operating profit) (NOPAT -477.8m / Invested Capital 601.7m)
WACC = 12.79% (E(288.3m)/V(297.2m) * Re(12.09%) + D(8.92m)/V(297.2m) * Rd(33.52%) * (1-Tc(-0.05)))
Discount Rate = 12.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.21%
[DCF Debug] Terminal Value 69.41% ; FCFE base≈48.1m ; Y1≈59.3m ; Y5≈101.2m
Fair Price DCF = 8.97 (DCF Value 933.3m / Shares Outstanding 104.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -40.86 | EPS CAGR: -57.23% | SUE: -3.90 | # QB: 0
Revenue Correlation: 24.11 | Revenue CAGR: 2.10% | SUE: 1.33 | # QB: 3
Additional Sources for DH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle